DeepSummary
The podcast episode features a discussion on the controversial GLP-1 agonist drugs like Ozempic, which are being used for weight loss and treating metabolic issues. It explores the macro perspective of the societal factors driving the obesity and metabolic crisis, including the toxic food environment, processed foods, and lack of lifestyle interventions. It also delves into the micro perspective of individuals struggling with metabolic dysfunction and whether these drugs could be a potential solution when lifestyle changes fail.
The conversation involves Dr. Tina Moore, who uses compounded, low-dose GLP-1 peptides in her practice, and Calley Means, who raises concerns about the pharmaceutical industry's profit motives and the lack of addressing root causes. They discuss the potential benefits and risks of these drugs, including regenerative effects, side effects, and the importance of combining them with lifestyle changes and not using them as a standalone solution.
The guests agree that while the current pharmaceutical approach is problematic, there may be a nuanced role for using these peptides in a different way, with lower doses, lifestyle interventions, and without promoting them as a lifelong solution. They acknowledge the need to fix the broader systemic issues driving the metabolic crisis while also exploring potential solutions for individuals struggling with metabolic dysfunction.
Key Episodes Takeaways
- The obesity and metabolic crisis in America is driven by a toxic food environment, ultra-processed foods, and a lack of lifestyle interventions.
- The pharmaceutical industry's approach to treating obesity with drugs like Ozempic is problematic, driven by profit motives and failing to address root causes.
- There may be a nuanced role for using GLP-1 agonists like Ozempic in a different way, with lower doses, combined with comprehensive lifestyle changes, and without promoting them as a lifelong solution.
- Compounded, low-dose GLP-1 peptides may have therapeutic and regenerative benefits beyond just weight loss, but proper management and dosing is crucial to avoid side effects.
- There is a need to address systemic issues driving the metabolic crisis while also exploring potential solutions for individuals struggling with metabolic dysfunction.
- The medical establishment and professional associations are influenced by pharmaceutical industry funding and may promote treatments without addressing lifestyle factors.
- Intensive lifestyle interventions and behavior change support are lacking in the current healthcare system due to lack of incentives and funding.
- Individual experiences and perspectives vary, with some finding benefits from using GLP-1 peptides as part of a comprehensive approach when lifestyle changes alone are not enough.
Top Episodes Quotes
- “We're in total alignment here. We were just talking before we came on that reports that ozempic cost about $5 to make. They're charging Americans and american taxpayers in many cases and more soon around $1,800 a month. And then Germany's paying like $60 a month. So the margins on this product are astounding. That's a scandal.“ by Calley Means
- “Well, the first thing I thought when I got invited onto this podcast was, well, I totally agree with those guys. So what am I going to do here? But I do have some nuanced information I want to share.“ by Tina Moore
Entities
Product
Company
Person
Organization
Book
Episode Information
The Doctor's Farmacy with Mark Hyman, M.D.
Dr. Mark Hyman
4/17/24
View the Show Notes From This Episode
Get Free Weekly Health Tips from Dr. Hyman
Sign Up for Dr. Hyman’s Weekly Longevity Journal
Like most things in life, when it comes to optimizing metabolic health, a nuanced perspective can help. Rather than viewing it as a black-and-white issue, we can take into consideration the big-picture social context we’re facing that encourages ultra-processed foods, obesity, and lifelong medication as well as the micro-level of what people are experiencing as individuals and understanding how to help them when all else fails. Today I’m thrilled to sit down with Dr. Tyna Moore and Calley Means for a grounded discussion that explores both sides of the spectrum, and everything in between.
In this episode, we discuss:
- The controversial discussion of GLP-1 agonists like Ozempic, weighing the pros and cons of these new drugs in treating obesity and metabolic crises (3:34)
- Challenging the notion of treating obesity with drugs like Ozempic (10:35)
- An unsettling revelation about the push for using Ozempic in children (12:04)
- Digging deeper into GLP-1 research and some of the benefits (32:51)
- Why are children being born metabolically challenged? (41:11)
- Dr. Moore’s approach to using peptides with her patients and for her own crippling pain, and what they’ve seen (45:19)
- How our current healthcare system lacks policies and support for behavior change (1:27)
While there are always differing views, we know for sure that our food and drug policies aren’t serving the best interests of creating sustainable, empowered health for the masses. I hope you’ll tune in to hear more from this comprehensive and lively discussion.
This episode is brought to you by Rupa Health, Pendulum, ARMRA Colostrum, and One Skin.
Streamline your lab orders with Rupa Health. Access more than 3,000 specialty lab tests and register for a FREE live demo at RupaHealth.com.
Pendulum is offering listeners 20% off their first month’s subscription of Akkermansia for gut health. Visit PendulumLife.com and use code HYMAN.
Save 15% on your first order of ARMRA Colostrum and unlock the power of 400+ functional nutrients. Just visit TryARMRA.com/Mark or use code MARK.
Unlock your healthiest skin yet. Try OneSkin with 15% off your first purchase using code HYMAN15 at OneSkin.co today.